Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

TAK-475 compared with and added to atorvastatin

Nov. 17, 2006

IND filed in India for ZYO-1

Nov. 16, 2006

Soliris BLA accepted for priority review

Nov. 16, 2006

NGD-4715 enters clinic for obesity

Nov. 15, 2006

Ospemifene, a next-generation SERM, could avoid menopausal hot flashes

Nov. 14, 2006

FDA extends Galvus review to accommodate new data

Nov. 14, 2006

Little skin transfer between partners seen with transdermal estradiol gel

Nov. 14, 2006

Mexican approval for Acomplia

Nov. 13, 2006

Novel cannabinoid CB1 receptor antagonists emerge from Pfizer R&D

Nov. 13, 2006

Recent patents describe novel antidiabetic agents

Nov. 13, 2006

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 15, 2026.
ASGCT 2026: Directed evolution in gene therapy
BioWorld
Directed evolution has become a central pillar in gene therapy. This engineering strategy enables the generation of more efficient variants of genetic editors and...
ASGCT 2026: Uncovering the mechanisms of AAV toxicity
BioWorld
Gene therapies rely on vectors to reach the target tissue where they act, such as adeno-associated viruses (AAVs) or lipid nanoparticles (LNPs), among other...
Biogen AD drug shows tau, cognition benefit, despite trial miss
BioWorld
Biogen Inc. has decided to advance diranersen (BIIB-080) into registrational trials for early Alzheimer’s disease, even though the antisense oligonucleotide...
Fosun secures rights to Aribio’s AR-1001 in potential $4.7B deal
BioWorld
Shanghai Fosun Pharmaceutical (Group) Co. Ltd. is paying $60 million up front for an option to secure exclusive rights to Aribio Co. Ltd.’s oral phase III-stage...